Multidisciplinary Study of Right Ventricular Dysplasia

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Frank Marcus, University of Arizona
ClinicalTrials.gov Identifier:
NCT00024505
First received: September 18, 2001
Last updated: January 15, 2013
Last verified: January 2013

September 18, 2001
January 15, 2013
September 2001
July 2010   (final data collection date for primary outcome measure)
Identifying the cardiac, clinical, and genetic aspects of ARVD [ Time Frame: Measured during the course of the study ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00024505 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Multidisciplinary Study of Right Ventricular Dysplasia
Multidisciplinary Study of Right Ventricular Dysplasia

The purpose of this study is to investigate the cardiac, clinical, and genetic aspects of arrhythmogenic right ventricular dysplasia (ARVD), a progressive disorder that predominantly affects the right side of the heart and causes ventricular arrhythmias.

BACKGROUND:

ARVD is an uncommon disorder but is considered a major cause of sudden death and life-threatening arrhythmia, in particular in the young population. The prevalence of ARVD is unknown but is certainly underestimated because of the difficulties in obtaining a correct diagnosis. It appears to be particularly frequent in certain geographical areas, probably for a founder effect, such as in northeast Italy, where a large number of ARVD cases and families have been described. A noncontrolled study of the University of Padua reported a frequency of familial forms of about 30 percent, indicating the existence of a defective gene in a large proportion of cases. In the United States the frequency of the disease is unknown, but the number of cases seems to be increasing.

The etiology of ARVD was unknown until very recently. The main hypothesis involved apoptotic mechanisms and, in some cases, a viral infection. However, in the last couple of years, two genes causing ARVD have been identified. The first one encodes plakoglobin, a protein of the cardiac junctions with adhesive and signaling functions. The second ARVD gene is the cardiac ryanodine receptor (RYR2), which has been characterized only very recently by Dr. Danieli's group. In fact, this discovery is so recent that in this study, RYR2 is still considered a potential candidate. The discovery of the first disease genes provides the basis for a candidate gene approach following the hypothesis of a "final common pathway." Thus, major candidates become genes involved in cell-cell adhesion and encoding ion channels.

DESIGN NARRATIVE:

This is a multidisciplinary, multicenter, collaborative study investigating the cardiac, clinical, and genetic aspects of ARVD. The specific aims are (1) to establish a North American ARVD Registry enrolling ARVD patients and their family members, based on standardized diagnostic test criteria, in a prospective longitudinal follow-up study; (2) to determine the genetic background of ARVD by identifying chromosomal loci and specific gene mutations associated with this disorder; (3) to determine the influence of the genotype on the clinical course of patients with ARVD and explore phenotype-genotype associations that will contribute to improved diagnosis, risk stratification, and therapy; and (4) to develop quantitative methods to assess right ventricular function in order to enhance the specificity and sensitivity of ARVD diagnosis.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Blood

Non-Probability Sample

Referals to enrolling centers from communities

  • Heart Diseases
  • Arrhythmogenic Right Ventricular Dysplasia
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
320
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females over the age of puberty
  • Suspected ARVD based on the presence of major or minor Task Force Criteria

Exclusion Criteria:

  • Children younger than 12 years of age
  • Internal cardioverter defibrillator (ICD) in place for more than 2 years (for probands)
  • Individuals with monomorphic ventricular ectopy of predominantly RBBB morphology
  • Individuals with obvious cardiomyopathic abnormalities of structure or function predominantly affecting the left ventricle
  • Individuals with other conditions that might be mistaken for right ventricular dysplasia such as congenital heart disease, e.g., atrial septal defect, anomalous drainage of the pulmonary vessels into the right atrium, and Ebstein's malformation
  • Individuals unwilling to undergo diagnostic testing at the nearest enrolling center
Both
12 Years to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00024505
983, U01HL065594-05, U01 HL65594, U01 HL65652, U01 HL65691
Yes
Frank Marcus, University of Arizona
University of Arizona
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Frank I. Marcus, MD University of Arizona
Principal Investigator: Jeffrey Towbin Baylor College of Medicine
Principal Investigator: Wojciech Zareba University of Rochester
University of Arizona
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP